We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Parquet, PJServant, DBailly, Det al.Monoamine oxidase inhibitor in the treatment of attention deficit disorder of residual type.A propos of a caseEncephale14/61988439–41Google Scholar
Wenker, PHGarfinkel, BDAttention Deficit Hyperactivity Disorder: Adult ManifestationsKaplan, HISadock, BJ 5th edComprehensive Textbook of Psychiatryvol 2Baltimore: Williams and Wilkins, 1989; 1837–41Google Scholar
Biederman, JNewcorn, JSpnah, SComorbidity of Attention Deficit Hyperactivity Disorder with conduct, depressive, anxiety and other disordersAm J Psychiatry148/51991564–77Google ScholarPubMed
Shakim, WOAsarnow, RFHess, E et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual stateCompr Psychiatry31/51990416–25CrossRefGoogle Scholar
Trott, GEFriese, HJMenzel, Met al.Use of Moclobemide in children with attention deficit hyperactivity disorder.Psyche-pharmacology1992; 106: S134–6CrossRefGoogle ScholarPubMed
Comments
No Comments have been published for this article.